Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor

Fig. 2

JARID1B overexpression correlates with advanced stages and worse overall survival (OS) in NSCLC patients. a Representative IHC staining of tissues from all-stage NSCLC patients showed concurrently increased JARID1B, c-Met, and Vimentin expression in stage 3 and 4 tumors as compared to stage 1 and 2 tumors. b Distribution of 29 NSCLC tumors with different stages according to Q-score values (p = 0.001). c The 5-year OS rates were 54.8% and 17.4% in JARID1B-low (n = 19) and JARID1B-high (n = 53) NSCLC patients, respectively (p = 0.009). Q-score ≥ 150 indicated JARID1B high and Q-score < 150 indicated JARID1B low

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us